SCHEMBL7982491

SCHEMBL7982491

O=C1CCCN1c1oc(-c2cc3ccccc3nc2Cl)nc1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.38
ALDH1A1 P00352 5/20 0.38
TDP1 Q9NUW8 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
MAPT P10636 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PKM P14618 1/20 0.34
AKT1 P31749 3/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
CNR2 P34972 1/20 0.33
FLT1 P17948 1/20 0.33
FLT4 P35916 1/20 0.33
KDR P35968 1/20 0.33
SLC2A1 P11166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7744215 0.89 KDM4E (0.39) KDM4EALDH1A1TDP1L3MBTL1NPC1
SCHEMBL7746666 0.73 KDM4E (0.41) KDM4EALDH1A1L3MBTL1MAPTNPC1
SCHEMBL7744109 0.71 KDR (0.54) CYP11B1CYP11B2FLT1FLT4KDR
SCHEMBL7969128 0.70 NOX1 (0.48) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL7982509 0.66 KDR (0.52) KDM4EMAPTNPC1RAB9APKM
SCHEMBL30644242 0.66 KDM4E (0.53) KDM4EALDH1A1TDP1L3MBTL1MAPT
SCHEMBL10816949 0.66 KDM4E (0.53) KDM4EALDH1A1TDP1L3MBTL1MAPT
SCHEMBL7982226 0.64 KDR (0.49) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL28377822 0.63 TOP2A (0.38) KDM4EALDH1A1NPC1RAB9AMAPK1
SCHEMBL5604821 0.61 HTR6 (0.56) KDM4EALDH1A1L3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6228871-B1 THIAZOLE OR OXAZOLE DERIVATIVE TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; AUTOIMMUNE DISEASES; DIABETIC RETINOPATHY MERCK & CO., INC. 2001-05-08 US disclosed